Is there any association between TACSTD2, KIAA1253, KU70 and mutant KRAS gene expression and clinical-pathological features of colorectal cancer?

Experimental Oncology

Volumn 33, Issue 1, 2011, Pages 28-32

  Ghezzi, T L ^a   Brum, I S ^a   Biolchi, V ^a   Garicochea, B ^b   Fillmann, L S ^b   Corleta, O C ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Gene expression; Intestine; Molecular biology; Neoplasm staging; Polymerase chain reaction

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; K RAS PROTEIN; KU ANTIGEN; MUTANT PROTEIN; PROTEIN SERIN1; TUMOR ANTIGEN; TUMOR ASSOCIATED CALCIUM SIGNAL TRANSDUCER; UNCLASSIFIED DRUG;

AGE; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNICITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION;

AGED; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 79953089263     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lozynska M. The prognostic value of cytogenetic markers for early diagnosis of colorectal cancer. Exp Oncol 2009; 31: 237-41.
2. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13:1438-46.
3. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-6.
4. Krtolica K, Krajnovic M, Usaj-Knezevic S, et al. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol 2007; 13: 1187-94. (Pubitemid 46592959)
5. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
6. Krens LL, Baas JM, Gelderblom H, et al. Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discov Today. 2010; 15: 502-16.
7. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003; 24: 703-10. (Pubitemid 36592405)
8. Wang J, Day R, Dong Y, et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008; 7: 280-5. (Pubitemid 351302522)
9. Ohmachi T, Tanaka F, Mimori K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006; 12: 3057-63. (Pubitemid 43837351)
10. Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290-5.
11. Nakashima K, Shimada H, Ochiai T, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 2004; 112: 1029-35. (Pubitemid 39507010)
12. Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008; 21: 186-91. (Pubitemid 351172170)
13. Alberti S, Miotti S, Stella M, et al. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma 1992; 11: 539-45.
14. Fradet Y, Cordon-Cardo C, Thomson T, et al. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1984; 81: 224-8. (Pubitemid 14180861)
15. Ky X, Gu J. Expression of TROP2 mRNA in left-sided and right-sided colon cancer and its clinical significance. Zhonghua Wei Chang Wai Ke Za Zhi 2009; 12: 285-9.
16. Fang YJ, Lu ZH, Wang GQ, et al. Elevated expression of MMP7, TROP2, and surviving are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009; 24: 875-84.
17. Gullo C, Au M, Feng G, et al. The biology of Ku and its potential oncogenic role in cancer - Review. Biochim Biophys Acta 2006; 1765: 223-34.
18. Velerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003; 22: 5792-812. (Pubitemid 37176701)
19. Walker JR, Corpina RA, Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 2001; 412: 607-14. (Pubitemid 32772267)
20. Komuro Y, Watanabe T, Hosoi Y, et al. Prognostic significance of Ku70 protein expression in patients with advanced colorectal cancer. Hepatogastroenterology 2005; 52: 995-8. (Pubitemid 40942170)
21. Komuro Y, Watanabe T, Hosoi Y, et al. The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer 2002; 95: 1199-205. (Pubitemid 35013052)
22. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23: 3526-35.
23. Watanabe T, Kobunai T, Sakamoto E, et al. Gene expression signature for recurrence in stage III colorectal cancers. Cancer 2009; 115: 283-92.
24. Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 2004; 15: 155-66.
25. Bustin SA, Benes V, Nolan T, et al. Quantitative real-time RT-PCR - a perspective. J Mol Endocrinol 2005; 34: 597-601. (Pubitemid 40903586)
26. American Joint Committee on Cancer. Collaborative staging task force of the American Joint Committee on Cancer. Collaborative staging manual and coding instructions, version 1.0. and U.S. NIH Publication Number 04-5496. [2010 Jan 7]. At: http://www.cancerstaging.org/cstage/csmanualpart1.pdf.
27. Greer CE, Peterson SL, Kiviat NB, et al. PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 1991; 95: 117-24.
28. Tol J, Dijkstra JR, Vink-Börger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2010; 14: 2122-31.
29. Cejas P, López-Gómez M, Aguayo C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009; 4: e8199.
30. Chang YS, Y KT, Chang TY, et al. Fast simultaneous of K-RAS mutations in colorectal cancer. BMC 2009; 9: 179, DOI: 10.1186/1471-2407-9-179.
31. Cubas R, Li M, Chen C, et al. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009; 1796: 309-14.
32. Urano M, Fuqiu H, Minami A, et al. Response to multiple radiation doses of human colorectal carcinoma cells infected with recombinant adenovirus containing dominant-negative Ku70 fragment. Int J Radiation Oncology Biol. Phys 2010; 77: 877-85.
33. Grabsch H, Dattani M, Barker L, et al. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 2006; 12: 1494-500.